Business
Cerus Corporation Announces Strategic Organizational Changes
Vivek Jayaraman promoted to Chief Operating Officer Dr. Nina Mufti promoted to VP Development and Red Blood Cell Program Leader Dr. Yasmin Singh promoted to
About this update from Cerus Corporation
[{"type":"text","content":"\nVivek Jayaraman promoted to Chief Operating Officer\n\n\nDr. Nina Mufti promoted to VP Development and Red Blood Cell Program Leader\n\n\nDr. Yasmin Singh promoted to VP Development and Platelet/Plasma/Therapeutics Program Leader\n\n CONCORD, Calif.--(BUSINESS WIRE)--\nCerus Corporation (Nasdaq:CERS) today announced the promotion of three key leaders within the Company in anticipation of the Company’s expected continued growth prospects, the anticipated approval and launch of multiple products over the next several years, as well as the need to realize greater operational effectiveness as the Company works to scale.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200302005230/en/Cerus Corporation announced the promotion of chief commercial officer Vivek Jayaraman to chief operating officer. (Photo: Business Wire)\n\n“These promotions from within our senior leadership team are intended to create an organizational structure that is focused on the ownership of key deliverables, both commercially and across our development portfolio, and are expected to provide Cerus with the continued growth opportunities required to achieve its mission of making INTERCEPT Blood System the global standard of care in transfusion medicine,” said William ‘Obi’ Greenman, Cerus’ president and chief executive officer. “Nina, Yasmin, and Vivek have led many of the activities that have been integral to Cerus’ recent achievements and I am excited to welcome them into new leadership roles so that the organization can benefit from their considerable experience and expertise. We expect this to be a transformative year for the company as we partner with our U.S. blood center customers as they adapt to comply with the recent FDA Guidance on the bacterial safety of platelets.”\n\n\nVivek Jayaraman, Chief Operating Officer\n\n\nMr. Jayaraman has served as Cerus’ chief commercial officer since August 2016. Since that time, global revenues have more than doubled. In his expanded role, Vivek will continue to lead commercial efforts while also providing leadership for the supply chain, customer service and manufacturing operations teams. “Vivek has played an instrumental role in our growth over the last several years, and we are excited to promote him into this position. With his advancement to chief oper...